The Pharmaceutical Research and Manufacturers of America (PhRMA) said on January 5 that Hiroo Igarashi, president of Pfizer Japan, has assumed the role of chair of its Japan-based Executive Committee (JBEC), effective January 1. Igarashi succeeds Simone Thomsen, president of…
To read the full story
Related Article
ORGANIZATION
- Ease Foreign Price Adjustment Rules for New Drugs to Counter MFN Policy: FPMAJ
June 15, 2026
- Raise Foreign Price Adjustment Cap for Listed Products in German Cases: FPMAJ
June 15, 2026
- FPMAJ Seeks Predictability in Price Maintenance System for Innovative Medicines
June 15, 2026
- LLP Extra Patient Charge Influences Generic Adoption at Over 40% of Hospitals: FPMAJ
June 15, 2026
- Society Envisions 1 Trillion Yen in Overseas Sales for Japan’s Off-Patent Drug Sector by 2040
June 9, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





